ID: ALA423373

Max Phase: Preclinical

Molecular Formula: C27H27N7O3

Molecular Weight: 497.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCCCNCCCNc1n[n+]([O-])c2ccccc2[n+]1[O-])c1cccc2cc3ccccc3nc12

Standard InChI:  InChI=1S/C27H27N7O3/c35-26(21-10-5-9-20-18-19-8-1-2-11-22(19)31-25(20)21)29-16-6-14-28-15-7-17-30-27-32-34(37)24-13-4-3-12-23(24)33(27)36/h1-5,8-13,18,28H,6-7,14-17H2,(H,29,35)(H,30,32)

Standard InChI Key:  NLUGECSVDGKXNQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 497.56

Molecular Weight (Monoisotopic): 497.2175

AlogP: 2.41

#Rotatable Bonds: 10

Polar Surface Area: 132.82

Molecular Species: BASE

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.47

CX Basic pKa: 10.20

CX LogP: 2.08

CX LogD: -0.47

Aromatic Rings: 5

Heavy Atoms: 37

QED Weighted: 0.12

Np Likeness Score: -0.63

References

1. Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA..  (2004)  DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.,  47  (2): [PMID:14711317] [10.1021/jm030399c]

2. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G..  (2017)  An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.,  142  [PMID:28851503] [10.1016/j.ejmech.2017.08.009]

Source

Source(1):

• Scientific Literature